Erika Martinelli

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

Andrea Sartore‐Bianchi, Livio Trusolino, Cosimo Martino et al. · The Lancet Oncology · 2016 · 1K citations · Full text

Medicine, Oncology, Pharmacology +14

HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer

Andrea Sartore‐Bianchi, Alessio Amatu, Luca Porcu et al. · The Oncologist · 2019 · 169 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Ralf‐Dieter Hofheinz, E Fokas, Léonor Benhaïm et al. · Annals of Oncology · 2025 · 129 citations · Full text

Medicine, Oncology, Surgery +14

Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer

Federica Tosi, Andrea Sartore‐Bianchi, Sara Lonardi et al. · Clinical Colorectal Cancer · 2020 · 104 citations · Full text

Medicine, Oncology, Pharmacology +17

Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case

Erika Martinelli, Teresa Troiani, Vincenzo Sforza et al. · ESMO Open · 2018 · 33 citations · Full text

Medicine, Molecular Medicine, Oncology +17